The Underexplored Journey by Carecho, Rafael et al.





Low Molecular Weight (poly)Phenol
Metabolites Across the Blood-Brain
Barrier: The Underexplored Journey
Rafael Carechoa,c, Diogo Carregosaa,b and Cláudia Nunes dos Santosa,b,c,∗
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Abstract. The world of (poly)phenols arising from dietary sources has been significantly amplified with the discovery of
low molecular weight (LMW) (poly)phenol metabolites resulting from phase I and phase II metabolism and microbiota
transformations. These metabolites, which are known to reach human circulation have been studied to further explore their
interesting properties, especially regarding neuroprotection. Nevertheless, once in circulation, their distribution to target
tissues, such as the brain, relies on their ability to cross the blood-brain barrier (BBB), one of the most controlled barriers
present in humans. This represents a key step of an under explored journey towards the brain. Present review highlights the
main findings related to the ability of LMW (poly)phenol metabolites to reach the brain, considering different studies: in
silico, in vitro, and in vivo. The mechanisms associated with the transport of these LMW (poly)phenol metabolites across the
BBB and possible transporters will be discussed. Overall, the transport of these LMW (poly)phenol metabolites is crucial to
elucidate which compounds may exert direct neuroprotective effects, so it is imperative to continue dissecting their potential
to cross the BBB and the mechanisms behind their permeation.
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(POLY)PHENOLS METABOLISM AND
DISTRIBUTION
Phenolic compounds and polyphenols, commonly
referred to as (poly)phenols, constitute a group of
small molecules widely spread mostly in plants, being
found in many fruits and vegetables. Their structures
having at least one hydroxyl group and one aromatic
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ring, together with functional groups have been linked
to a huge variety of beneficial properties to human
health, some of them related with brain health [1–3].
Since they easily reach our organism through our
daily diet, their impact on human’s health may be
relevant. Therefore, to reveal their potential effects,
several studies focused on understanding their routes
after being ingested, the metabolism they are submit-
ted, the distribution to reach the target tissues, and
ultimately, the mechanisms behind their action. It has
been established that the (poly)phenols influence the
brain by modulating receptors function, interacting
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with neuronal signaling pathways, and by promot-
ing the expression of proteins mainly involved in
synaptic plasticity and neuronal repair [1–3]. The out-
comes emerged from this research allow the scientific
community to state the bioavailability and bioactivity
of many dietary phenolic, especially flavonoids, and
explore their role in several chronic diseases [1–3].
Importantly, dietary (poly)phenols are subjected to
several biotransformations after oral intake. Phase I
and phase II enzymes are responsible for intensive
catabolism over the parent compounds both in the
intestine and in the liver, leading to a broad range of
(poly)phenol metabolites [1, 3, 4]. Moreover, they
may undergo further metabolism in the colon by
the gut microbiota into simpler compounds to be
absorbed [5, 6]. All (poly)phenols, from simple phe-
nolics to more complex ones, are submitted to this
biotransformation. As result, the molecules that reach
circulation and are able to influence the tissues are
not anymore the same complex molecules present in
the food consumed, but novel metabolites that have
arisen from the gastrointestinal tract metabolism [1,
3, 7–9]. Along time, many mechanistic studies have
been reporting the molecular effects on cellular mod-
els of isolated parent compounds without considering
the processes of absorption and the metabolic reac-
tions that (poly)phenols undergo within the human
body. From those studies, some conclusions have
been drawn that may not fit with results in vivo, where
the influence of the described metabolic events over
the compounds occurs.
Overall, colonic microbiota and liver metabolism
originates a huge variety of metabolites. Some of
them are unique metabolites derived from a specific
parent compound (e.g. urolithins from ellagitannins,
S-equol from isoflavones) [9, 10] but the major-
ity of them, derived possibly from several parent
compounds, are simpler metabolites named low-
molecular-weight (LMW) (poly)phenol metabolites
(Table 1). These LMW (poly)phenol metabolites are
considered to reach circulation at considerably higher
concentrations (10–30 M) than their parent com-
pounds [1, 9].
Concerning the effect of (poly)phenol metabo-
lites on brain function, it is still unclear whether
their effect derives from direct action on brain cells
or/and an indirect mechanism by affecting peripheral
and cerebrovascular blood flow [2]. Considering the
abundance of the LMW (poly)phenol metabolites and
their relatively small structures, it is plausible to con-
sider that these compounds could play the main roles
in the direct effect on brain cells. Bearing this in mind,
we previously reviewed the molecular mechanisms
underlying LMW (poly)phenol metabolites effects,
describing the scientific evidence of the bioactivity of
these metabolites in the brain and their specific role
on neuroinflammation [9]. The current review will
focus on the data available for the brain bioavailabil-
ity of these human LMW (poly)phenol metabolites,
including evidence of crossing BBB in silico, in vitro,
and in vivo.
Before emphasizing the data related to brain
bioavailability of LMW (poly)phenol metabolites
derived from the diet, it is important to state all pos-
sible origins of these compounds within the human
body and the implication for brain function. Some
of the gut microbes and host enzymes involved
in the described biotransformations are responsible
for the general metabolism of any chemical sub-
stance not naturally produced by or expected to
be present within the human organism (xenobiotic
metabolism). Therefore, it is not surprising that these
LMW (poly)phenol metabolites could be obtained
in humans not only through the regular diet, but
also by metabolizing other ingested compounds, like
residues of industrial chemicals and pharmaceuticals
[11].
In fact, many of these compounds appear described
as intermediates of xenobiotics biodegradation and
metabolism pathways like the bacterial aminoben-
zoate degradation pathway [12]. On the other hand,
it is also known that some of these compounds could
appear in human circulation due to endogenous ori-
gin, due to the overlap with endogenous pathways
such as the tyrosine or dopamine pathways [12].
Regardless of the mode of occurrence within the
human body (by endogenous production or by dietary
exposure to parent compounds) for some LMW
(poly)phenol metabolites their presence in different
human organs is already described in the human
metabolome database (Table1) [13]. Moreover, since
some of them are endogenously produced, we could
expect a biological function in a specific pathway as
indicated in Table 1. In fact, for some of these metabo-
lites we highlighted the pathways where they could be
involved, using the KEGG pathways database [12].
Additionally, since these metabolites share chemical
similarities with some endogenous compounds it is
also expected that some could interfere in the same
pathways. Benzene diols metabolites due to their cat-
echol moiety appear mentioned as involved in the
metabolism of catecholamine neurotransmitters and
catechol hormones, as substrate or products from
catechol-O-methyltransferase (COMT) activity [12],
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Table 1
LMW (poly)phenol metabolites disposition within human organism and pathways that are affect by those compounds. LMW (poly)phenol
metabolites considered were detected in humans circulating in plasma or excreted in urine after dietary flavonoids ingestion1
Compound class Common name Organs detected Pathways that could be involved
(HMD)2 (KEGG)3






Predicted to be involved in COMT activity in the





Guaiacol – Predicted to be involved in COMT activity in the




































Benzoic acid derivatives benzoic acid Testicle/Bladder/
Liver/Skin/Kidney
–
salicylic acid Liver/Skin –
3-hydroxybenzoic acid – –
4-hydroxybenzoic acid Cerebrospinal Fluid –












vanillic acid – –
vanillic acid-4-O-sulfate – –
vanilic acid-4-O-glucuronide
Dihydroxybenzoic acids 2,4-dihydroxybenzoic acid – –
gentisic acid – Product of tyrosine metabolism
2,6-dihydroxybenzoic acid – –
3,5-dihydroxybenzoic acid – –
(Continued)
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Table 1
(Continued)




gallic acid – –
3-O-methylgallic acid – –




syringic acid – –
ethyl gallate – –
Phenylacetic acids






2-(3-hydroxyphenyl)acetic acid – Product of phenylalanine metabolism
2-(4-hydroxyphenyl)acetic acid Bladder/Epidermis/
Kidney/Prostate




or homoprotocatechuic acid or
DOPAC
Brain Product of dopamine metabolism by monoamine
oxidase (MAO) and further metabolized by COMT
homovanillic acid Brain/Central Nervous
System/Kidney/Spinal
Cord
Product of dopamine metabolism after DOPAC
metabolism by COMT
Mandelic acids
Mandelic acid mandelic acid – –
Hydroxymandelic acid 4-hydroxy-mandelic acid Retina/Vitreous humor –
Dihydroxymandelic acid Vanillylmandelic acid Adrenal
Gland/Epidermis/
Thyroid Gland
Product of tyrosine metabolism
Hippuric acids
Benzoylglycine hippuric acid Kidney/Liver/Prostate Product of phenylalanine metabolism
Hydroxy Benzoylglycine
derivatives
3-hydroxyhippuric acid – –
4-hydroxyhippuric acid – –
Cinnamic acids
Cinnamic acid Cinnamic acid Liver
Hydroxycinnamic acids m-coumaric acid – –
p-coumaric acid – –
o-coumaric – –
Dihydroxycinnamic acids caffeic acid Prostate –
isoferulic acid – –
ferulic acid – –










dihydrocaffeic acid – –
dihydroferulic acid – –









1For more details concerning the presence in plasma or excreted in urine of the low molecular weight phenolic metabolites in humans after
dietary flavonoids ingestion see review [9]. 2The Human Metabolome Database (HMDB) (http://www.hmdb.ca/) was used for searching
available information concerning metabolites source (endogenous or by exposure) and the organs were have being described to be detected
[13]. 3KEGG (Kyoto Encyclopedia of Genes and Genomes) database(https://www.kegg.jp/kegg/) was used to localize the metabolite in the
KEGG pathways using the organism-specific pathway: Homo sapiens (human) [12]. The presence of the enzymes in humans was confirmed
in BRENDA database (https://www.brenda-enzymes.org) [16].
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while pyrogallol and phloroglucinol are inhibitors of
the same enzyme [12, 14, 15]. Phenylacetic acids are
mainly involved in aminoacid metabolism, pheny-
lalanine, and tyrosine metabolism and as by-products
of dopamine metabolism. Consequently, this is also
the class of phenolic metabolites with more evidences
in the human metabolome database of being detected
in human brain [13]. Surprisingly, there is scarce data
concerning their disposition within human organs and
pathways that could be involved (Table 1).
Notably, the ability of metabolites in circulation
to reach the target tissues is very important when
considering their final effect. Their distribution relies
on their capability to cross several barriers they may
encounter during their journey. Regarding the ner-
vous system, they will face one of the most regulated
and controlled barriers in the human body, the blood-
brain barrier (BBB), that must be crossed to directly
influence the brain [17].
BBB AND BBB DYNAMICS
BBB is a complex and highly selective semi per-
meable barrier found in most of the blood vessels
that irrigate the brain, acting as a border between
the circulating blood and the extracellular space of
the central nervous system (CNS) [18]. It is formed
by multiple cell types and proteins that ensure tight
regulation of the movement of ions, molecules, and
cells between the blood and the brain. This regula-
tion allows controlling the accessibility of nutrients
and molecules needed for brain homeostasis. It also
prevents the entrance of toxins, pathogenic agents,
and other harmful molecules that could impair the
brain homeostasis. However, in an increased state of
inflammation like in chronic diseases, BBB becomes
more permeable, allowing the infiltration of viruses
and bacteria. For the BBB to work properly, it requires
the presence of tight junctions, which are central
components of the barrier structure. Tight junctions
maintain the endothelial cells attached to each other
and restrict the passage by diffusion across the blood
vessels [19]. Also, the astrocytes have an important
role by projecting their end-feet to the walls of blood
vessels, as well as the pericytes, which are involved in
both endothelial cells support and paracrine signaling
[19, 20].
Having this in mind, phenolic metabolites that
reach the systemic circulation towards neuronal tis-
sue are faced with this selective barrier that separates
them from the brain. Meaning that, crossing the BBB
represents a crucial step for metabolites in order to
directly affect our brain.
In fact, this issue is not fully understood, and
the mechanisms by which phenolic metabolites per-
meate the BBB are still unknown. The structure
of metabolites should affect the effective uptake of
these metabolites by the brain. Also, the routes used
to access the brain might differ due to the struc-
tural differences of metabolites. Youdim et al showed
that permeation across the BBB is associated with
lipophilicity, meaning polar metabolites like sulfate
and glucuronide conjugates will have reduced pas-
sage through the BBB by comparison with less polar
methylated conjugated [21, 22]. Thus the degree
of lipophilicity/polarity of each compound is a key
factor that will determine transport by simple dif-
fusion. Nevertheless, the primary route by which
(poly)phenols cross the BBB: diffusion or specific
carrier-mediated transport, is still not clear [23].
Moreover, the specific efflux transporters expressed
in endothelial cells of BBB should be considered.
These transporters may decrease the apparent per-
meability of the BBB to metabolites by transporting
them back to the blood stream [24]. The question
remains, however, whether the effects of phenolic
metabolites on the modulation of brain functions are
mediated directly in the brain or can be caused by
peripheral cells as well since both scenarios are plau-
sible. Additionally, recent studies have been reported
the ability of endothelial cells to metabolize the
phenolic metabolites into novel compounds before
allowing their penetration into the brain [25]. Con-
cerning this, more attention must be paid to the
post-absorption events and intracellular metabolic
reactions. This will allow us to distinguish what
bioactive compounds are capable of affecting brain
cells by modulating neuronal signaling pathways.
As the evidence of anti-inflammatory properties
attributed to (poly)phenols in the brain increases
(reviewed in [9, 26, 27]), the focus turned to their
capacity to cross the BBB, and different approaches
from in silico, cell-based, and in vivo assays have
been used to address that issue.
TRANSPORT OF LMW (POLY)PHENOL
METABOLITES THROUGH THE BBB
In silico predictions of passive permeation
Although the presence of the LMW (poly)phenols
metabolites has been confirmed in circulation as men-
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tioned, the mechanisms by which these molecules
cross the cell membranes into circulation and reach
target organs are still quite underexplored, especially
in the case of the brain. Several types of membrane
transport have been considered for (poly)phenols.
For flavonoids, several mechanistic studies on their
transport have been proposed, due to their molecular
weight and other chemical properties like polar sur-
face and number and position of the oxygen atoms
among others discussed below. The main idea of
a transport, based on passive transport, has been
substituted by the concept of flavonoids transport
be mediated by ATP-binding cassette transporters
(ABC) and organic anion transporters (OAT) [3] and
also organic anion transporting polypeptides (OATP)
[28, 29]. However, in the case of LMW (poly)phenol
metabolites, the facts about their transport is still
largely unknown.
Considering that the transport of (poly)phenol
metabolites across cell membranes is known to be
either through passive permeation, or active trans-
port [23, 30, 31], this could potentially be extended
to LMW (poly)phenol metabolites as well. Never
the less, in the case of small molecules, defined
as <500 g/mol, and their potential transport through
BBB, one of the most studied possibilities is pas-
sive permeation [25, 32–34]. Passive permeation
depends on the physical-chemical properties of a
molecule and could be predicted by in silico methods.
Yet, a limited number of studies have been con-
ducted on LMW (poly)phenol metabolites molecules.
These methods rely on physical-chemical parame-
ters denominated by molecular descriptors, that are
intrinsic to a molecule, for example molecular weight,
number of hydrogen acceptor and donor bounds,
volume, dipole moment, and many others [32]. All
these parameters can then be conjugated into a sin-
gle property designated commonly as log BB that
represents the logarithmic ratio between the con-
centration of a compound in the brain and blood.
This log BB property can then be used to compare
between a library of known molecules that cross the
BBB and the potential molecules to predict. Many
of these models are present in the literature and are
usually associated with drug discovery [35]. Due
to the different molecular descriptors used for each
model, a direct comparison between log BB can-
not be made and are usually model- dependent. The
ability of several LMW (poly)phenol metabolites to
passively cross the BBB according to different in
silico models are reported in Table 2. The number
of studies found on LMW (poly)phenol metabo-
lites passive permeation was quite limited and data
was only found for 23 of the described molecules
in Table 1. Overall, most of the molecules evalu-
ated demonstrate some probability of crossing the
BBB, although this probability cannot be quanti-
tative, it is indicating only that if the presence is
expected in the brain it is due to passive perme-
ation. One of the exceptions is salicylic acid where
in silico predictions projected as not probable to
reach the brain. However, this molecule has been
detected in the rat brain and its presence was associ-
ated with transport-mediated mechanisms [36]. For
some of these compounds like protocatechuic and
vanillic acid different estimates were given by differ-
ent predictive models, demonstrating that the model
used can influence the conclusions taken about pas-
sive permeability. All molecules analyzed in QikProp
software seemed to indicate, through log BB, that the
molecules could reach the brain. Nevertheless, dif-
ferent conclusions were drawn with SWISS ADME
where di and tri-substituted phenolic acid metabo-
lites (vanillic acid, protocatechuic acid and, gallic
acid) were stated as not probable of crossing the
BBB. Furthermore, SWISS ADME predicts ferulic
acid has a molecule able to cross the BBB, together
with p-coumaric and cinnamic acid but not sinapic
acid. Information regarding other classes of LMW
(poly)phenol metabolites like hippuric acids and pro-
pionic acids would greatly increase our knowledge
of passive permeation for these types of molecules.
Nevertheless, this data is still missing. Overall, in
silico predictions since are less labor-intensive, inex-
pensive and high throughput, are quite useful for
initial information about the potential of a metabo-
lite to cross the BBB. Initial in silico screening in
a set of compounds allows refining further anal-
ysis in the more technically challenging process
of obtaining detailed in vivo BBB permeability
data for the most promising compounds. A good
example of this rationale was the comprehensive
study that was done for the flavan-3-ols metabo-
lites, phenyl--valerolactones, phenylvaleric acids,
and their conjugates. This study explored through an
in silico analysis the most promising molecules which
were tested in a cell-based assay. Finally, the presence
of the above mentioned compounds was validated in
the brain in three different in vivo studies [33]. It will
be very interesting to perform a comparative study
for all described LMW (poly)phenols metabolites in
the same model of passive permeation - an evaluation
that, to the best of our knowledge, to date still has not
been done.
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Table 2
– In silico studies on LMW (poly)phenol metabolites for passive permeation across the BBB




Catechol PreADMET v2.0 Probable [37]
catechol- O-sulfate QikProp 2015-4 Probable [25]
pyrogallol- O-sulfate QikProp 2015-4 Probable [25]
1- O-methylpyrogallol- O-sulfate QikProp 2015-4 Probable [25]
2- O-methylpyrogallol-1- O-sulfate QikProp 2015-4 Probable [25]
4-methylcatechol- O-sulfate QikProp 2015-4 Probable [25]
Benzaldehydes Protocatechualdehyde QikProp 2009 Probable [38]
benzoic acid StarDrop Probable [39]
PreADMET v2.0 Probable [37]
salicylic acid In house based on
GROMACS 4.5.5
Not probable [40]
4-hydroxybenzoic acid SWISS ADME Probable [41]
PreADMET v2.0 Probable [37]
protocatechuic acid QikProp 2009 Probable [38]
SWISS ADME Not probable [41]
PreADMET v2.0 Probable [37]
Benzoic acids vanillic acid QikProp 2009 Probable [38]
SWISS ADME Not probable [41]
PreADMET v2.0 Probable [37]
vanillic acid-4- O-sulfate QikProp 2015-4 Probable [25]
gallic acid SWISS ADME Not probable [41]
4-O-methylgallic acid QikProp 2015-4 Probable [25]
4-O-methylgallic acid-3-O-sulfate QikProp 2015-4 Probable [25]
syringic acid SWISS ADME Not probable [41]
Phenylacetic acids 2-(4-hydroxyphenyl)acetic acid PreADMET v2.0 Probable [37]
caffeic acid QikProp 2009 Probable [38]
ferulic acid QikProp 2009 Probable [38]
SWISS ADME Probable [41]
Cinnamic acids p-coumaric acid SWISS ADME Probable [41]
sinapic acid SWISS ADME Not probable [41]
cinnamic acid SWISS ADME Probable [41]
1The probability of the molecules to passively cross the BBB is defined by each of the models used: QikProp: Molecules probable of
crossing the BBB should have a log BB between -3 and 1.2 [42]. StarDrop: Molecules are classified by the authors as not probable or
probable according to the log BB of -1 or higher than -1 respectively [39]. In house model using GROMACS 4.5.5: Molecules are probable
of crossing the BBB if logPeff is above 0 [40]. SWISS ADME: Based on the information given by the authors, molecules are probable to
reach the brain if Log Po/w is in the range of 1.5 to 2.7 [41]. PreADMET v2.0: Authors present BBB crossing probability as a percentage.
All molecules with BBB(%) above 0.1 are considerately probable of crossing the BBB [37].
Cell based data on BBB permeability
In vitro cell-based studies, mostly taking advan-
tage of brain endothelial cellular models, have been a
very important tool to address the ability of metabo-
lites permeation across the BBB endothelium in a
more realistic way. For some flavonoids and their
known circulating metabolites, the permeability was
tested on in vitro models of the BBB [21]. The
uptake of hesperetin, naringenin, and their respec-
tive in vivo glucuronides, as well as the anthocyanins
cyanidin-3-rutinoside and pelargonidin-3-glucoside
has been reported in two brain endothelial cell lines
from mouse (b.END5) and rat (RBE-4). In this study
flavonoids permeation across in vitro BBB mono lay-
ers was compared to the potential for permeation
for their more polar glucuronidated conjugates and
to specific phenolic acids derived from colonic bio-
transformation of flavonoids. The authors concluded
that hesperetin and naringenin present a high appar-
ent permeability [21]. Moreover, in another study,
both catechin and epicatechin were able to cross two
BBB cell lines, RBE-4 cells and hCMEC/D3 (immor-
talized human cerebral micro vessel endothelial cell
line) in a time-dependent manner [43]. In vitro trans-
membrane transport of flavonols, flavan-3-ols and
anthocyanins and some of their methylated and glu-
curonidated metabolites were also observed in the
hCMEC/D3 cells [44]. Interestingly, the authors con-
cluded that in most cases, the metabolites exhibited
higher transport efficiency than their unconjugated
parent compounds [44]. Overall, data strongly sug-
gest the effective uptake of dietary (poly)phenols
and their metabolites through the BBB endothelium.
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Table 3
– Evidence of transport of LMW (poly)phenol metabolites in cellular models of the blood-brain barrier based in brain endothelial cells




catechol-O-sulfate HBMEC 5 2 7.7 ± 0.6 [25]







4-methylcatechol-O-sulfate 12.6 ± 1.9
pyrogallol BBB kit (RBT-24)1 30 0.5 2.84 ± 0.27 [45]
pyrogallol-1-O-glucuronide 1.91 ± 0.29
Benzoic acids vanillic acid-4-O-sulfate HBMEC 5 2 2.5 ± 1.2 [25]




gallic acid BBB kit (RBT-24)1 30 0.5 6.5 ± 0.6 [46]




dihydroferulic acid BBB kit (RTU)2 10 1 medium [47]
dihydrocaffeic acid capacity3
Abbreviations: HBMEC, Human Brain Micro vascular Endothelial cells; BBB, Blood-brain barrier. 1BBB Kit™ (RBT-24) is anin vitro model
of BBB made of primary cultures of rat (Wistar rat) brain capillary endothelial cells, brain pericytes, and astrocytes. 2BBB kit (RTU) is an in
vitro model of BBB consisting of endothelial cells from bovine brain capillaries. 3According to the authors, compounds were classified into
3 categories considering their ability to cross the BBB, based on their permeability coefficient (Pe): low capacity (Pe < 1 × 10–3 cm.min–1),
medium capacity (1 × 10–3 cm.min–1 < Pe < 2 × 10–3 cm.min–1) or high capacity (Pe > 2 × 10–3 cm.min–1). Pe values were calculated for
ferulic acid (1.31 ± 0.20 Pe ( × 10–3 cm.min–1), dihydroferulic acid 1.20 ± 0.24 Pe ( × 10–3 cm.min–1) and dihydrocaffeic acid 1.01 ± 0.1
Pe ( × 10–3 cm.min–1).
However, there are very few studies focusing on the
LMW (poly)phenols metabolites and their ability to
reach the brain. In fact, a huge potential in this field
has been underestimated, and only for a few classes
such as benzene diols and triols, benzoic acid, and
cinnamic acid data was collected (Table 3).
In a recent study, the endothelium transport
of some known LMW (poly)phenol metabolites,
products of sulfate conjugations was addressed by
using a human brain micro vascular endothelial
cell (HBMEC) line [25]. The same model was
used to confirm flavan-3-ols metabolites BBB
permeability followed by in vivo validation [33].
The BBB cellular models consist of the ability
to cultivate cells on a transwell that divides two
separate chambers mimicking the luminal (blood)
and the abluminal (brain) sides separated by brain
micro vascular endothelial cells. Catechol-O-sulfate,
pyrogallol-2-O-sulfate, 1-O-methylpyrogallol-O-
sulfate, 2-O-methylpyrogallol-1-O-sulfate, vanillic
acid-4-O-sulfate, 4-O-methylgallic acid, and 4-O-
methylgallic acid-3-O-sulfate have been tested for
BBB permeability and all of them were detected in
the abluminal side [25]. However limited amounts
of these LMW metabolites were observed to be
transported, ranging from 1.3 to 12.6% of transport
[25]. One of the possibilities to originate the low
passive diffusion could be the involvement of efflux
transporters pumping back the metabolites to the
luminal side. In the same study the efflux transporters
P-gp, BRCP, and MRP1 activity were tested in the
cells for the transport of some LMW (poly)phenols
metabolites and the percentage of transport was not
significantly affected [25]. Interestingly, phase II
derivatives, sulfated and methylated, presented a
higher percentage of transport comparing to their
counterparts, suggesting being more prone to be
brain permeable. In any case, passive permeation
may not be the only method of transport across the
BBB, since it could also be mediated by carriers
[25].
Some ready-to-use BBB model kits were already
tested for LMW (poly)phenol metabolites BBB
permeability. In that sense, resorting to the BBB
kit (RBT-24), made of primary cultures of rat
brain endothelial cells, pericytes and astrocytes, the
transport for gallic acid, pyrogallol and pyrogallol-1-
O-glucuronoide was demonstrated [45,46]. Despite
of the pyrogallol is less polar than gallic acid, this
last one presented a higher permeation since it is
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known that it can be incorporated into cells through
an organic anion carrier (OAT3) [48]. Furthermore,
another commercially available in vitro model of
BBB (RTU), consisting of bovine endothelial cells,
was used to test the potential of ferulic acid, dihy-
droferulic acid, and dihydrocaffeic acid to cross the
BBB [47]. In fact, none of these metabolites presented
a high capacity to cross these endothelial cells, pre-
senting permeability coefficient (Pe) values slightly
above the adopted cutoff value of 1 × 10–3 cm.min–1
(Table 3). This means that their permeation to the
brain could be considered as negligible. This medium
capacity to cross the BBB, could result, as men-
tioned before, from a low passive diffusion or even
can be due to the involvement of efflux transporters
pumping back the metabolites to the luminal side. In
opposition, in Madin-Darby Canine Kidney (MDCK)
cells, which is considered a useful model to eval-
uate cell permeability, ferulic acid rapidly crossed
this barrier, increasing the transport rate overtime,
reaching approximately 25% [49]. In a different
BBB model consisting of ECV-304 bladder carci-
noma cells and C6 glioma cells in co-culture, also
described as a good indicator of BBB permeability,
the authors were unable to detect the transport of (3,4-
dihydroxyphenyl) acetic acid, 3-(4-hydroxyphenyl)
propionic acid and 2-(4-hydroxyphenyl) acetic acid
[21].
Interestingly, in silico predictions about the per-
meability of the specific molecules with available
information show corroborating data between in vitro
and in silico predictions. However, the number of in
vitro studies is still limited to generalize this valida-
tion of the in silico data.
Still, although the data available regarding LMW
(poly)phenols BBB permeability is scarce, it has
gained a lot of attention since the BBB represents
the entrance door to reach the brain. Noteworthy,
sometimes the goal of the research is to find methods
to avoid brain penetration of toxins and potentially
dangerous molecules but sometimes it is convenient
to promote the entrance of drugs. An interesting
branch of research has been focusing on increasing
the efficiency of drug delivery with the purpose of
overcoming the tight regulation characteristic of the
BBB. In that sense, sinapic acid, conjugated with
a zwitterionic polymer in an encapsulated bovine
serum albumin-based nanoparticles, proved to be a
novel bioinspired BBB-permeable ligand for delivery
of cargo into the brain [50], which is seen as a key
factor for the therapeutic efficacy in the treatments of
CNS-related diseases.
In vivo experiments confirm the presence of
LMW (poly)phenol metabolites in the brain
For a full comprehension regarding the brain
uptake of phenolic metabolites, in vivo experiments
are crucial since they are the only way to fully reca-
pitulate the complexity of the BBB. Being this a very
emergent issue, several studies have been interested in
confirming the brain bioavailability of (poly)phenols,
having already been identified some of them in dif-
ferent brain regions of rats [51, 52] and pigs [53, 54]
which can accumulate in a non regional-specific man-
ner [55]. Micro dialysis sampling in rats also showed
the presence of (+)-catechin and (–)-epicatechin in
the brain, demonstrating their ability to cross the
BBB [56]. The exact localization and target sites
of (poly)phenols in the brain represent an important
aspect for understanding its molecular mechanism
but this issue remains unlooked. The main reason for
this is the fact that the major analytical approach for
this evaluation in biological samples relies on chro-
matographic techniques. Some attempts to address
this was done by using monoclonal antibodies for
the compounds [57, 58]. Also, the brain presence
of (poly)phenols seems to be independent of their
route of administration, since different compounds
were detected in the brain after different types of
administration. For instance, epigallocatechin gallate
[59, 60], epicatechin [61–64], anthocyanins [52, 65],
quercetin [66, 67] and naringenin [68], were detected
in the brain after oral administration while naringenin
and its glucuronide were also detected after intra-
venous injection [69] as well as hesperetin that was
detected in the brain striatum [70]. However, there
are some contradictory results as is the case of antho-
cyanins that could not be detected in brains of rats
after supplementation with raspberry juice in a dose
equivalent to 700 mL to a 70 kg human [71] but were
detected in other experimental designs that involved
either higher doses or chronic administration [52, 72,
73]. For analysis of a compound penetration in the
brain it is the gold standard to use exsanguinated or
perfused animals or a correction for residual blood
in the brain [23]. This was one critical aspect that
has raise some controversy since these appropriated
control procedures were lacking in some studies.
By contrast to the dietary (poly)phenols, only a
very limited number of studies have focused on LMW
(poly)phenol metabolites, although some evidence
can be found of their potential to cross the BBB and
reach the brain. Among predictive studies, whose out-
comes provide an idea about the ability of metabolites
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to cross the BBB endothelium by passive diffusion
and in vitro studies that can give us a wide-ranging
clue about their permeation, both approaches are still
limited. On the other hand, in vivo models, despite
being based on rodent and pig models, are those
that get closest to recapitulate the human physiol-
ogy, undergoing the influence of natural processes of
a living organism. This means that in animal studies
the brain bioavailability of phenolic metabolites will
be influenced by different cell types, enzymes, trans-
porters, endogenous molecules, etc. mimicking in a
better way the organism environment.
Although limited, evidence of the BBB capac-
ity to uptake LMW (poly)phenol metabolites using
in vivo models have been increasing in the litera-
ture. However the main findings attained in these
studies, have different experimental designs, partic-
ularly regarding the animal model, the gender, the
type of administration, the dose, and the compounds
sourced, hampers an exact comparison. Within this
section, we review some of these studies, highlight-
ing the compounds that were tested to cross the
BBB, the dosage, and the brain uptake, using in
vivo models. An important difference in these stud-
ies, that lead to different conclusions, is the type
of administration of the (poly)phenols. Compounds
were sourced either by extract form or pills being
administered intragastrically or orally mixed with the
diet (Table 4), or they can be administered them-
selves directly either by intravenous or intraperitoneal
injection (Table 5). The difference between these two
approaches is the metabolic route that compounds
will follow. If they enter the organism orally, the
pharmacokinetics of the metabolites increase the dif-
ficulty for the exact quantification of the amount that
reaches the brain and the calculation of the proportion
that is brain-bioavailable. The extensive metabolism
over the (poly)phenols, present in the extracts, by the
microbiota and the entero-hepatic enzymes, will lead
to difficulties in estimating the concentration of a spe-
cific metabolite in blood and the kinetics (Tmax, T1/2)
associated with their presence. On the other hand, if
the administration is directly in the blood stream it
will bypass most hepatic metabolic pathways, reach-
ing the tissues faster and making it easier to know
with more accuracy the percentage that reached the
brain.
Margalef et al. have administered orally different
acute doses (125, 250, 375, and 1000 mg/Kg BW) of
grape seed (poly)phenol extract (GSPE) to the male
rats [74]. The total of 16 different phenolic acids that
generate a set of phase II metabolites found at differ-
ent concentrations in different tissues were identified
from this extract [74]. As expected, given that the
brain is a peripheral organ difficult to cross, metabo-
lites that were quantified in this tissue presented much
lower concentrations than those found in the liver and
kidney. Notably, 4 of the human LMW (poly)phenol
metabolites (listed on Table 1) were detected in brain
plus phenylpropionic acid, an LMW (poly)phenol
metabolite detected in rodents, being that a propor-
tional increase with the increased dose of GSPE was
not observed. Benzoic acid, 3-hydroxybenzoic acid,
homovanillic acid, and hippuric acid were detected
after 2 hours of GSPE ingestion. In turn, gallic acid,
3-O-methylgallicacid, and 4-hydroxyhydrocinnamic
acid were not detected in the brain of these rats for any
dose tested, despite being detected in other organs in
the same animals. Moreover, gallic acid was present
in the extract and 4-hydroxyhydrocinnamic acid
could be generated by the metabolism of quercetin-3-
O-galactoside, which was also present in GSPE [74].
The same authors evaluated if the GSPE extract could
originate a brain accumulation of the metabolites
after a long-term administration in the rats [75]. The
authors concluded that the concentrations detected
in the brain, 21 hours after daily GSPE adminis-
tration of 100 mg/Kg BW for 12 weeks, do not
reflect an accumulation but instead originated from
the last acute administration dosage [75]. This con-
clusion was based on the fact that flavanol metabolites
in plasma were not detected 21 hours after GSPE
administration [75]. Moreover, very few metabolites
were detected in the studied tissues and at lev-
els much lower than the total amounts that were
quantified 2 hours after a single GSPE ingestion of
a similar dose in the previous study [74]. In the
study, conducted by Wang et al., also using GSPE
administered for 11 days, the content for 12 LMW
(poly)phenol metabolites in the brain were analyzed
[76]. Among the 12 screened compounds 8 were
found in the brain but only 3-hydroxyhydrocinnamic
acid and 3-hydroxybenzoic acid were found signifi-
cantly increased compared with the control animals
(4.5 and 2.5-fold change respectively). Hippuric acid,
4-hydroxybenzoic acid, 3-hydroxyphenylacetic acid,
homoprotocatechuic acid, dihydrocaffeic acid and
phenylacetic acid were also detected in the brain, but
no differences were found compared with rats with-
out GSPE [76]. This differential profile of the LMW
(poly)phenol metabolites detected in the brain using
the same source the GSPE extract could be due to sev-
eral reasons. One possibility is the time of analysis,


















– Evidence of in vivo brain uptake of LMW (poly)phenol metabolites after oral administration
Compound
class
Common name Study design Brain uptake References
Animal Food Matrix Dosage Units Frequency Type of Euthanasia Time (nmol/g of









Single Intragastric Exsanguination 2 h 15.63 ± 2.40 [74]
250 2.53 ± 1.40
375 18.88 ± 2.96















Single Intragastric Exsanguination 2 h 0.61 ± 0.13 [74]
250 0.43 ± 0.18
375 0.44 ± 0.04

















Intragastric Perfusion 6 h 1.36 ± 0.14 [76]
250 1.75 ± 0.30
protocatechuic
acid
Balb/cA mice Powder diet 2 g of PCA
mixed with
98 g of diet
g Supplied for
12 weeks
Oral Not described 0.26 ± 0.10 [77]























Intragastric Perfusion Detected (trace levels) [79]





























Common name Study design Brain uptake References
Animal Food Matrix Dosage Units Frequency Type of Euthanasia Time (nmol/g of











Single Intragastric Exsanguination 2 h 2.36 ± 0.48 [74]
250 2.11 ± 0.23
375 1.84 ± 0.44




















Single Intragastric Not described 5 h 0.39 ± 0.048 [81]
10 0.32 ± 0.028
100 0.40 ± 0.058
Hippuric
acids




Single Intragastric Exsanguination 2 h 0.32 ± 0.10 [74]
250 0.56 ± 0.18
375 0.42 ± 0.21























Intragastric Perfusion 6 h 1.49 ± 0.14 [76]







5 g/Kg BW Single Intragastric Exsanguination 2 h 15 ± 01.1 [82]
Abbreviations: GSPE,Grape seed (Poly)phenol extract; PCA, Protocatechuic acid; BW, Body weight. 1GSPE was provided by used was Meganatural-AZ® GSPE as described by the authors.
5Hydroxytyrosol was provided by Seprox Biotech (Madrid, Spain)as described by the authors. 6Hazelnut extract was provided by La Morella Nuts S.A. (Reus, Spain) as described by the authors
was a source of procyanidins. 7The original value (0.09 ± 0.07 g of protocatechuic acid /mL of microdialysis brain sample) presented by the authors was converted to nmol/g of tissue considering
the brain density of 1 g.cm−3 and the molecular weight of PCA (154.12 g/mol). 8Homovanillic acid was also detected in the vehicle group and only for the highest dose (HT-100) homovanillic
presented significant increases in the brain. 9The original value (0.4 g of ferulic acid/g of wet tissue) presented by the authors was converted to nmol/g of tissue considering the molecular weight


















– Evidence of in vivo brain uptake of LMW (poly)phenol metabolites after either intravenous or intraperitoneal injection of the metabolites
Compound class Common name Study Design Brain uptake References




catechol Inbred strain of
mice (male)
5.5 × 105a nmol/Kg BW Intraperitoneal Decapitation 290d [83]
Inbred strain of
mice (female)
5.5 × 105a Decapitation 304e [84]
pyrogallol Inbred strain of
mice (male)
1.1 × 106b Decapitation 350f [83]
Inbred strain of
mice (female)
4.8 × 105c Decapitation 220g [84]
Benzoic acids vanillic acid Wistar rats (male) 50 nmol Intravenous 0.385 [51]
4-hydroxybenzoic acid 100 Decapitationh 0.408
gallic acid 900 0.611
Phenylacetic acids homoprotocatechuic acid 75 0.501
homovanillic acid 50 0.433
Hippuric acids 4-hydroxyhippuric acid 250 0.020
Cinnamic acids caffeic acid 60 0.0038






Abbreviations: BW,Body weight. aThe original value (60 mg/Kg BW) presented by the authors was converted to nmol/Kg BW considering the molecular weight of catechol (110.1 g/mol). bThe
original value (120 mg/Kg BW) presented by the authors was converted to nmol/Kg BW considering the molecular weight of pyrogallol (126.1 g/mol). cThe original value (60 mg/Kg BW) presented
by the authors was converted to nmol/Kg BW considering the molecular weight of pyrogallol (126.1 g/mol). dThe original value (32 g/g of tissue) presented by the authors was converted to
nmol/g of tissue considering the brain density of 1 g.cm–3 and the molecular weight of catechol (110.1 g/mol). eThe original value (33.5 g/g of tissue) presented by the authors was converted to
nmol/g of tissue considering the brain density of 1 g.cm–3 and the molecular weight of catechol (110.1 g/mol). f The original value (44 g/g of tissue) presented by the authors was converted to
nmol/g of tissue considering the brain density of 1 g.cm–3 and the molecular weight of pyrogallol (126.1 g/mol). gThe original value (28.4 g/g of tissue) presented by the authors was converted
to nmol/g of tissue considering the brain density of 1 g.cm–3 and the molecular weight of pyrogallol (126.1 g/mol). hAs the concentrations of the metabolites in the brains may be significantly
influenced by the amount of each metabolite present in the residual blood, the authors have made a correction by estimating the amount of each metabolite in intravascular blood present in the
brain, considering the volume of brain blood as 47.7 L/g.
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metabolites present in the brain was done 6 hours
post-GSPE administration [76] the opposite of 2 and
21 hours post-administration in the previous studies
[74, 75]. LMW (poly)phenol metabolites appearance
in circulation in vivo peaks around 6 hours post-
consumption and have longer elimination half-life
[85, 86]. Accordingly, it is not clear if a chronic
consumption vs. acute ingestion could impact the
levels detected since there is no a direct compari-
son for the same time point of tissue collection after
the last intake. Another aspect that may account for
different results is the fact that these studies have
used different rat strains (Sprague-Dawley vs. Wistar
rats) whose endocrine system was described as dif-
ferent and this causes differences in food conversion
and food intake [87]. Altogether, these differences
in the experimental design may justify the qualita-
tive and quantitative differences found in the rats’
brains of LMW (poly)phenol metabolites in both
studies.
Concerning the presence of gallic acid in the brain,
another study also using Sprague-Dawley rats, like-
wise has not detected this metabolite in the brain
when rats were orally gavaged with acute doses of
GSPE (50, 100 or 150 mg/Kg BW) [79]. Only upon
repetitive dosing with GSPE for 10 days, trace levels
of gallic acid were detected [79]. In another study,
gallic acid was also not found in the brain of con-
trol animals that were orally treated with Gualou
Guizhi granules, a standard prescribed drug from
Traditional Chinese Medicine. In the same trial,
however, the rats that were subjected to cerebral
ischemia/reperfusion injury and, treated also with
the Gualou Guizhi granules, presented higher per-
meability of BBB, favouring the passage of several
metabolites, including the gallic acid [88]. The BBB
integrity is an important factor, even though BBB
is highly regulated, towards an insult or a disease it
may be disrupted, and therefore it increases its per-
meability, favouring the entrance of molecules that
otherwise would not enter.
Protocatechuic acid was detected in the brain of
rats that received Danshen extract intragastrically
(containing danshensu 40 mg/Kg BW, protocatechuic
aldehyde 149 mg/Kg BW and salvianolic acid B
50 mg/Kg BW) [78]. Additionally, male Balb/cA
mice with a diet supplemented with protocatechuic
acid have also shown increased levels of this metabo-
lite in the brain, which were not detectable in brains
from mice not supplemented [77]. Ferulic acid was
also found in the brain of rats that took Shunaoxin
pills, a traditional Chinese medicine product enriched
in ferulic acid. It was showed that ferulic acid is
rapidly absorbed and distributed in the brain, being
detectable 5 minutes after the administration and no
longer at 4 hours [49].
Although not derived from colonic metabolism,
metabolites derived from intake of hydroxytyrosol
food sources, like virgin olive oil, are also LMW
(poly)phenol metabolites. Homovanillic acid and
some related metabolites detected in rodents like
homovanillic acid sulfate and homovanillic alco-
hol sulfate, were detected in the brains of the rats
5 hours after an acute high dose of hydroxyty-
rosol (100 mg/Kg BW) [81]. All these metabolites
appear in the brain of control animals derived from
dopamine metabolism which masks the appearance
of the metabolites for the intake of lower doses of
hydroxytyrosol. Homovanillic alcohol sulfate was
also reported to increase in brains of rats that
consumed daily standard diet supplemented with
5 mg/Kg BW of either hydroxytyrosol or hydroxyty-
rosol derivatives for 21 days [89]. Moreover, sulfates
of vanillin, vanillic acid and homovanilic were also
detected in the brain of rats after the ingestion of
phenolic extract from olive cake [80].
Interestingly a significant gender effect in the
plasma, liver, and kidney concentrations of hydrox-
ytyrosol metabolites was observed [81]. However,
no gender effect was observed in the uptake of
hydroxytyrosol metabolites in the brain and heart
[81]. On the other hand, gender effects were con-
sidered to influence brain uptake of (poly)phenols
in the case of GSPE derived flavanol metabolites
where differences between males and females were
observed [74, 90, 91]. Being (poly)phenols recog-
nized by the human organism as xenobiotics, it is
not surprising to observe differences between genders
in its metabolism. Such differences can be potenti-
ated by age, estrous/menstrual cycle and pregnancy.
Generally, it is described that male rodents tend to
have higher levels of cytochrome P450, while phase
II metabolism seems to be quite similar between
genders. Some reports, however, show higher glu-
curonidation in males in the liver, compensated
with higher glucuronidation in the female kidney.
Moreover, some CYP450 expression seems to be
sex-specific, and their expression levels quite differ-
ent between genders meaning the rate of metabolism
and excretion can be highly dependent on the sub-
strate [92]. Gender affects the balance between
the sulfation, glucuronidation, and methylation of
(poly)phenols and the way how xenobiotics affect
metabolic enzymes in the liver of rats is also different
R. Carecho et al. / LMW (poly)phenol metabolites across the Blood-Brain Barrier 207
between sexes [90]. It has been reported for in vitro
models of BBB that estrogens may play a role in mod-
ulating free flavanol uptake, and it has been further
suggested that progesterone can act as an endoge-
nous factor that modulates P-glycoprotein ability
to serve as transporters of flavan-3-ol’s across the
BBB [43].
Another approach to evaluate brain permeabil-
ity to (poly)phenol metabolites in vivo is its direct
administration to the circulation bypassing the
gastrointestinal tract (Table 5). In that sense, a
pharmacokinetic study tried to uncover the fate of
microbial metabolites of dietary (poly)phenols upon
intravenous injection in the dorsal penis vein of rats
[51]. The injection site allows the minimal manipu-
lation of anesthetized animals avoiding the release of
inflammatory mediators that might affect BBB per-
meability, the normal distribution, and excretion of
metabolites. From the 23 metabolites present in the
mixture injected, 18 are LMW metabolites described
in Table 1. From these, 13 were found in con-
trol brains as endogenous but only 9 were found
increased compared to the control group (Table 5).
Among them, caffeic acid has reached the brain at 15
minutes at approximately 34 times the basal concen-
tration (0.11 pmol/g of tissue) and has presented the
biggest difference between controls and injected rats,
but it was the one detected in lower concentration
(3.81 pmol/g of tissue). On the other hand, vanillic
acid presented the highest percentage of transport
to the brain considering both the dose injected
and the mean concentration found in control brains
[51]. Interestingly within the 9 LMW (poly)phenol
metabolites, the top 4 that presents the higher per-
centage of transport are all phenolic acids (gallic
acid < 4-hydroxybenzoic acid < homoprotocatechuic
acid < homovanillic acid < vanilic acid). In fact, an
interesting consideration could be made about these
molecules, since homovanillic acid, one of such top 4
molecules was already described to be transported in
rats brain by the activity of the Organic Anion Trans-
porter 3 (rOAT3) [93]. Based on this, we may expect
that this type of transport could also be occurring for
other phenolic acids.
In an attempt to identify circulating hydroxyty-
rosol metabolites and their deposition in tissues,
D´Angelo, and colleagues injected intravenously
radiolabelled 14C hydroxytyrosol in Sprague-
Dawley rats [94]. Although the radioactivity up
taken by the brain was lower than in other
organs, besides the hydroxytyrosol, homovanil-
lic alcohol, 3,4-dihydroxyphenylacetaldehyde, 3,4-
dihydroxyphenylacetic acid, homovanillic acid and
sulfate conjugates were also detected in the brain.
The authors consider that some of these metabolites
were presumably derived from enzymatic activities
operating in the brain, like methylation that reflects
COMT activity [94]. In fact, in order to evaluate the
effects of hydroxytyrosol and its nitro derivatives
on COMT activity, compounds were administered
into the rat striatum through a microdialysis probe
[95]. All compounds increased extracellular levels of
3,4-dihydroxyphenylacetic acid during the perfusion
and did not produce a decrease in the extracellular
homovanilic acid suggesting their effect as COMT
inhibitors [95]. The same results were observed
in rats that received either an acute (single dose;
20 mg/Kg, i.p.) or chronic (one daily dose for 5
days; 20 mg/Kg, i.p.) treatment with the compounds
[96].
Another study has addressed the penetration of
catechol and pyrogallol into male mouse brain
after intraperitoneal injection of 60 mg/Kg BW and
120 mg/Kg BW respectively, being both compounds
detected in the brain [83]. Similar observations were
made in female mice after the administration of both
compounds intraperitoneally [97]. In both studies,
catechol and pyrogallol reached the brain at very
high concentrations, reflecting the supraphysiologi-
cal concentrations administered to mice. Although it
was not the goal of these studies, the results do not
indicate noticeable sex differences in the ability of the
compounds to reach the brain. However, this could be
an important factor to be considered in futures stud-
ies, since the sex dimorphisms in many aspects of
COMT’s function are already described and therefore
relevant for benzene diols/triols and also dihydrox-
yphenylacetic acids. For instance, it was detected a
prominent sex differences in the impact of tolcapone,
COMT inhibitor, on dopamine metabolite levels.
Specifically, females showed a greater tolcapone-
related change in 3,4-dihydroxyphenylacetic acid in
prefrontal cortex and cerebellum, and in homovanilic
acid in the prefrontal cortex and striatum [98].
In fact, gender effects were already considered to
influence (poly)phenol brain uptake as previously
discussed.
Concerning these data, different conclusions can
be drawn if the proper interpretation is not made.
There are many variables between studies regard-
ing their experimental designs that influence the
amount and type of LMW (poly)phenol metabolites
detected in the brains that should be taken into con-
sideration. From the studies herein presented, the
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Fig. 1. – LMW (poly)phenol metabolites journey to and through the brain. Black arrows represent passage and distribution of the molecules
into the brain. Dashed orange arrows represent putative metabolism inside the brain. Dashed arrows represent possible methods of distribution
to and from the brain observed for other xenobiotics and predicted for LMW (poly)phenols metabolites.
source of (poly)phenols is quite wide and variable
and even the regular diet given to the rats can be dif-
ferent. The time of fasting and the time after the last
(poly)phenol administration and the quantification
are critical parameters that generate different results.
As we already highlighted, the rat strain and gender,
the concentration of the compound, as well as the
route and the frequency of the administration have
also a strong influence on the amount and type of
LMW metabolites able to reach the brain.
BBB TRANSPORTERS AND FURTHER
METABOLISM
The mechanisms by which LMW (poly)phenol
metabolites cross the BBB are still quite underex-
plored. As stated previously, passive permeation and
carrier mediated transport could constitute a poten-
tial mechanism by which these molecules could cross
the BBB and potentially reach the brain. However,
other mechanisms of transport are also considered,
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such as paracellular transport and vesicular transport
(Fig. 1). Studies with parent flavonoids suggest that
they are transported by ABC, OAT and also OATP
[28, 29] transporters and that are responsible for most
of the absorption and distribution of flavonoids within
the body as well as their excretion in urine [3]. On
the other hand several ABC transporters were iden-
tified in the BBB such as P-pg (ABCB1), MRP1
(ABCC1), MRP2 (ABCC2), MRP4 (ABCC4) and
BCRP (ABCG2) [99]. Therefore, it is plausible to
consider that the same transporters could be involved
in the transport of the residual levels of flavonoid cir-
culating and most importantly the transport of their
more abundant LMW (poly)phenol metabolites. Yet,
a study using HBMEC cells showed no impact of
P-gp, MRP1 or BCRP on the transport of some of
these metabolites [25]. For some LMW (poly)phenol
metabolites like phenolic acids, interactions with
OAT transporters such as OAT1 (SLC22A6), OAT3
(SLC22A8), and OAT4 (SLC22A11) was already
demonstrated [100, 101]. The transport of 3,4-
dihydroxyphenylacetic acid and homovanilic acid,
two LMW (poly)phenol metabolites but also products
of dopamine metabolism (Table 1) are known to be
transported across the BBB through OAT3 [93, 102].
This observation could reveal an important starting
point for understanding how these molecules traverse
the brain and reach the cerebrospinal fluid [93, 102].
Glucuronidation could also be a way of transport for
xenobiotics. Glucuronide metabolites of morphine
have been suggested to be transported across the BBB
by glucose transporter 1 (GLUT1), organic anion
transporters (OATs) and organic anion-transporting
polypeptide (OATP1A2) [103, 104]. This could also
be a possibility for LMW (poly)phenol metabolites
to distribute across the brain similarly.
Other types of transport may also be considered,
especially in the disease context. These include vesic-
ular transcytosis and paracellular transport that are
strictly regulated in the BBB and are a less probable
method for these types of compounds to reach the
brain. Nevertheless, it has been proven that perme-
ation through these two methods can be compromised
in diseases within which inflammation occurs lead-
ing to an increase permeability of BBB to small
molecules [105, 106].
There is still huge gap in knowledge about the
fate of LMW (poly)phenol metabolites in the brain,
especially due to the diversity of brain resident
cells (Fig. 1). The fate of these LMW (poly)phenol
metabolites should coincide with other xenobi-
otic molecules as well as endogenous molecules
from the tyrosine or dopamine pathways. In the
BBB and inside the brain, several phase I and II
enzymes are known to be present. Phase I enzymes
include CYP1B1, CYP2D6, CYP2E1, CYP2J2,
CYP2U1 CYP46A1, CYP1B1 CYP1A1, CYP2U1,
CYP3A5, CYP2R 1, CYP2E1, CYP2D6, capa-
ble of triggering (de)hydroxylation, (de)methylation
and (de)alkylation reactions [107]. Moreover, a
vast array of conjugation phase II enzymes can
be found such as: glutathione-S-transferase 4
(GST4), glutathione S-transferase Mu 3(GSTM3),
catechol-O-methyl transferase (COMT)and sulfo-
transferase1A4 (SULT1A4) [107]. Some studies have
already demonstrated that some of these LMW
(poly)phenol metabolites could undergo these types
of metabolic reactions in vitro when incubated in the
presence of the human brain microvascular cells [25].
Also, some catechin glucuronides were detected in
the abluminal side in BBB models with RBE-4 and
hCMEC/D3 cells, indicating the presence of UDP-
glucuronyltransferases within the cells [43]. These
types of metabolites could have an important function
in vivo, yet much is awaiting to be discover regarding
(poly)phenol metabolism in the brain.
CONCLUSION
(Poly)phenols’s brain effects research reached a
moment where it is crucial to embrace and clarify
the discovery of which metabolites are reaching the
brain. Several approaches have been used to under-
stand this potential ranging from in silico, in vitro
and in vivo methods. Understanding which are the
metabolites from the dietary (poly)phenols that can
in fact cross the BBB and reach the brain is impera-
tive to further explore their potential benefits to the
brain.
For some metabolites (4-hydroxybenzoic acid,
vanillic acid, p-coumaric acid, ferulic acid, caffeic
acid, protocatechuic acid) the in silico predictions
of brain permeability were validated in in vivo stud-
ies. Also, the predicted inability to cross the BBB
by sinapic acid could reflect its absence in the rat
brain [51]. But this verification lacks for all metabo-
lites. For example, SWISS ADME model seemed to
predict gallic acid has not able to reach the brain
by passive permeation, however it can be found in
some experimental designs at relevant concentrations
in the rat brain [51]. In silico models only reflect
passive permeation and other possibilities should
also be consider in vivo. Also the conclusions made
from in vivo studies should be take with precau-
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tion, different conclusions about the percentage of
brain permeability of (poly)phenols can be drawn
if the proper interpretation is not made. There are
many variables between studies regarding their exper-
imental designs that influence the amount and type
of LMW (poly)phenol metabolites detected in the
brains that should be taken into consideration. The
source of (poly)phenols is quite wide and variable
and even the regular diet given to the rats can differ.
Food complexity and interactions among the different
components can affect the release of the compounds
from the matrix and the uptake leading to different
pharmacokinetic profiles. Moreover, the experimen-
tal design concerning the time of collecting the tissues
for analysis after the last (poly)phenol administra-
tion will define the metabolites that will be detected
and quantified in the brain. Additionally, as already
highlighted, the rat strain, the concentration, the fre-
quency and the route of the administration have also
a strong influence on the amount and type of LMW
(poly)phenol metabolites able to reach the brain.
Sex differences may have also an important impact
and it is a factor that most studies do not account.
(Poly)phenols that target the brain are probably the
physiologically active forms.
Understanding the mechanisms by which LMW
(poly)phenol metabolites reach the brain will also
impact the development of (poly)phenol derivatives
as potential drugs with better pharmacokinetic prop-
erties. Another aspect, still in its infancy, is the
knowledge on the potential enzymes and bio trans-
formations that these compounds may be submitted
to when entering the brain and once inside the brain.
These further metabolic reactions may be decisive
for their potential activity. Altogether, the presence
and concentration in circulation, the percentage of
crossing the BBB and the metabolism of LMW
(poly)phenol metabolites is crucial if the objective is
to design nutritional and pharmacological approaches
to create a link between dietary factors and the pre-
vention or treatment of neurodegenerative diseases.
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